New York Medical College - Saint Michael's Medical Center, Newark, NJ
Sindhusha Veeraballi , Wajeeha Aiman , Amaar Ahmad , Navjot Grewal , Murad Qirem , Samer Jumean , Sahar Memar Montazerin , Muhammad Ashar Ali , Gunwant K. Guron , Hamid Salim Shaaban
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive tumor and is one of the leading causes of cancer related deaths worldwide. Kirsten Rat Sarcoma (KRAS)mutation resulting in tumor cell proliferation and cancer progression is a frequently mutated oncogene in various cancers and is approximately seen in 90% of pancreatic ductal adenocarcinoma. Efforts are being done to target Kras mutation in the last 3–4 decades. Here in, we report the results of the systemic review of clinical trials done on chemotherapeutic agents targeting Kras mutated pancreatic cancer. Methods: We followed PRISMA guidelines to conduct this systematic review. A literature search was performed on PubMed, Clinicaltrials.gov, and Embase with mesh terms, “pancreatic neoplasm’’ and “kras” from the inception of data till 01/05/2023. We screened 4191 articles and included 3 clinical trials with published study results and 3 ongoing clinical trials. Results: In this systematic review, data on 2 chemotherapeutic agents Sotorasib (AMG510) and Adagrasib (MRTX849) which are Kras G12C inhibitors, are obtained from Code Break-100 and preliminary results of KRYSTAL-1 clinical trials, respectively. In these 2 clinical trials (N-48), all the patients had advanced pancreatic cancer with Kras G12C mutation and were previously treated with chemotherapy. 10 patients in Krystal-1 trial, who received adagrasib showed progression-free survival (PFS) of 6.6 months, disease control rate (DCR) of 100 % and partial response (PR) of 50%. 38 patients in the Code Break-100 trial, who received Sotorasib showed PFS of 4 months, DCR of 84.2% and PR of 21.1%. However, 50% of patients in the KRYSTAL-1 trial are still receiving treatment. Grade 3 /4 adverse events were seen in 21% and 16% of patients in the KRYSTAL-1 and Code Break-100 trial, respectively. Other Kras G12C inhibitors like D-1553, Sotorasib in combination with 2nd line chemotherapy are under investigation. Results of a clinical trial on anti KrasG12D siRNA done on locally advanced pancreatic cancer patients showed a median overall survival of 15.12 months with no dose limiting adverse events. A multinational randomized phase 2b clinical trial is ongoing for the evaluation of efficacy of siRNA based drug in combination with chemotherapy. Conclusions: Both Adagrasib and Sotorasib showed promising results in the pretreated Kras G12C pancreatic cancer patients with acceptable safety profile. Further exploration of these drugs and their combination with other chemotherapeutic agents is necessary.
Author | Drug regimen | N | ORR | Complete response (CR) | (PR) | DCR | Overall survival (OS) | PFS |
---|---|---|---|---|---|---|---|---|
Bekaii-Saab et al. 2022 | Adagrasib (MRTX849) | 10 | 50% so far | NA | 50% | 100% | 50% pts Ongoing treatment | 6.6 months |
Strickler, J. H et al. 2023 | Sotorasib | 38 | 21% | 0% | 21.1% | 84.2% | 6.9 months | 4 months |
Golan, T et al.2015 | Anti KrasG12D siRNA + chemotherapy | 12 | NA | NA | 25% at 6 months follow up | 13.3% | 15.12 months | NA |
60% at 8.5 months follow up |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Tanios S. Bekaii-Saab
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Tanios S. Bekaii-Saab
2023 ASCO Annual Meeting
First Author: Tariq Arshad
ASCO Plenary Series
First Author: John H Strickler